A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

NCT ID: NCT06716424

Last Updated: 2026-01-21

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 105 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-06
• Study Completion Date: 2026-06-26

Brief Summary

This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.

Detailed Description

The study duration will be up to 27 weeks, with a treatment duration approximately 24 weeks.

Conditions

Type 2 Diabetes

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

iGlarLixi

iGlarLixi will be administered to study participants subcutaneously

Group Type: EXPERIMENTAL

iGlarLixi (insulin glargine/lixisenatide)

Intervention Type: DRUG

iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously

Interventions

iGlarLixi (insulin glargine/lixisenatide)

iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously

Intervention Type: DRUG

Other Intervention Names

Soliqua®, Solostar®

Eligibility Criteria

Inclusion Criteria

• Participants must be ≥18 years of age, at the time of signing the informed consent
• Participants with Type 2 Diabetes diagnosed for at least 1 year at the time of screening on treatment with Metformin +/- OADs or basal insulin/GLP-1RA for a minimum period of 6 months prior to screening
• HbA1c between ≥ 7.5% and ≤10.5% inclusive, during screening
• Participant with BMI >= 25 kg/m2 (as per Endocrine Society of India, Ref 12)
• Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 1 week after the last dose of study intervention (i.e., until Week 27)
• Signed informed consent

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

• Type 1 Diabetes mellitus or any diabetes other than T2DM
• Prior use of any combination of Basal Insulin + GLP-1 RA Fixed Ratio or Free Combination, Premix Insulin, Basal bolus therapy
• Basal insulin dose >50 U at screening
• Any clinically-significant abnormality identified either in medical history or during screening evaluation (e.g., physical examination, laboratory tests, electrocardiogram, vital signs) or any AEs during screening period, which in judgment of the Investigator would preclude safe completion of the study or constrains efficacy assessment
• Known presence of factors that interfere with the HbA1c measurement (e.g., specific hemoglobin variants, hemolytic anemia) compromising the reliability of HbA1c assessment or medical conditions that affect interpretation of HbA1c results (e.g., blood transfusion or severe blood loss in the last 3 months prior to baseline, any condition that shortens erythrocyte survival)
• History of severe hypoglycemia requiring emergency room admission or hospitalization within 3 months prior to screening visit
• Proliferative retinopathy or maculopathy requiring treatment according to the Investigator
• Use of weight loss drugs (including over-the-counter and herbal medications) within 12 Weeks prior to the screening visit
• Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 2 weeks or more within 8 weeks prior to screening visit
• Likelihood to require treatment prohibited by the protocol during the study.
• Exposure to any investigational drugs in the last 4 weeks or 5 half-lives, whichever is longer, prior to screening visit or concomitant enrollment in any other clinical study involving an investigational study treatment
• Any specific situation during study implementation/course that may raise ethics considerations
• History of hypoglycemia unawareness
• Patients with known hypersensitivity to lixisenatide, insulin glargine or to any of the inactive ingredients in the formulation
• History of drug or alcohol abuse within 6 months prior to screening visit

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Investigational Site Number : 3560007

Delhi, , India

Investigational Site Number : 3560005

Hyderabad, , India

Investigational Site Number : 3560006

Indore, , India

Investigational Site Number : 3560011

Jaipur, , India

Investigational Site Number : 3560003

Kanpur, , India

Investigational Site Number : 3560001

Kolkata, , India

Investigational Site Number : 3560008

Pune, , India

Investigational Site Number: 3560013

Pune, , India

Investigational Site Number : 3560014

Visakhapatnam, , India

Countries

India

Related Links

https://sanofi.trialsummaries.com/Study/StudyDetails?id=26355&tenant=MT_SNY_9011

LPS18016 Plain Language Results Summary

Other Identifiers

LPS18016

Identifier Type: -

Identifier Source: org_study_id

U1111-1303-3494

Identifier Type: REGISTRY

Identifier Source: secondary_id